Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint – SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE)...